亚洲综合大片69999,日韩一区二区三区aaa,亚洲av熟女国产一区二区三区视,国产亚洲一区二区三区精品久久

加入收藏 | 設(shè)為首頁(yè) | 聯(lián)系我們

產(chǎn)品搜索

產(chǎn)品分類(lèi)

聯(lián)系我們

聯(lián)系人：蔣經(jīng)理
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com

產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73196KIF5B（E15）-RET（E12） V804M/BaF3

KIF5B（E15）-RET（E12） V804M/BaF3
名稱(chēng) KIF5B（E15）-RET（E12） V804M/BaF3
型號(hào) CBP73196
報(bào)價(jià)
特點(diǎn) KIF5B（E15）-RET（E12） [V804M]/BaF3,母細(xì)胞：BaF3，凍存條件：90% FBS+10% DMSO
  • 詳細(xì)內(nèi)容
CBP73196
I. Introduction

Cell Line Name：

KIF5B(E15)-RET(E12) [V804M]/BaF3

Host Cell:

BA/F3

Stability:16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RRPMI-1640+10%FBS

Mycoplasma Status:

Negative


II.Background

Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC). These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468. They are typically identified in young patients with adenocarcinoma histology and minimal smoking history. Therapeutic targeting of RET-fusion–driven NSCLCs has taken the form of treatment with broad-spectrum tyrosine kinase inhibitors with anti-RET activity, such as cabozantinib (Cabometyx; Cometriq), vandetanib (Caprelsa), lenvatinib (Lenvima), RXDX-105, and sunitinib (Sutent). Cabozantinib and vandetanib have been the most heavily studied multi-kinase inhibitors (MKIs), with response rates of 20% to 50% in largely pretreated patients with RET-rearranged NSCLC. Sunitinib has been used in fewer patients to date with initial results demonstrating a 22% response rate. RXDX-105 has exhibited uniquely impressive response rates (75%) in patients with non–KIF5B-RET-fusion NSCLC, compared with 0% response in patients with KIF5B-RET-fusion–positive NSCLC. BLU-667 has demonstrated an objective response rate of 50% in patients with RET-fusion positive NSCLC, and LOXO-292 reported a 74% ORR in patients with RET-fusion positive NSCLC. Notably, RXDX-105, BLU- 667, and LOXO-292 have all demonstrated some central nervous system activity in these early phase trials. Future directions of RET inhibition in patients with RET-rearranged NSCLC include additional clinical validation of the next generation RET-selective inhibitors RXDX-105, BLU-667, and LOXO-292 and comparing multikinase inhibitors with RET-selective inhibitors to determine the optimal sequencing of RET-targeted therapies.


III. Representative Data

1. WB of  KIF5B-RET [V804M]/BaF3

CBP73196 WB.png


2. Sanger of KIF5B-RET [V804M]/BaF3

CBP73196 sanger1.png

CBP73196 sanger2.png


3. Anti-proliferation assay


CBP73196 fig.jpg

Figure 4. CTG Proliferation Assay of BaF3 KIF5B-Ret(S) V804M Cells (C1).




如果你對(duì)CBP73196KIF5B（E15）-RET（E12） V804M/BaF3感興趣，想了解更詳細(xì)的產(chǎn)品信息，填寫(xiě)下表直接與廠家聯(lián)系：


留言框

  • 產(chǎn)品：

  • 您的單位：

  • 您的姓名：

  • 聯(lián)系電話：

  • 常用郵箱：

  • 省份：

  • 詳細(xì)地址：

  • 補(bǔ)充說(shuō)明：

  • 驗(yàn)證碼：

    請(qǐng)輸入計(jì)算結(jié)果（填寫(xiě)阿拉伯?dāng)?shù)字），如：三加四=7

化工儀器網(wǎng)

推薦收藏該企業(yè)網(wǎng)站
国产精品粉嫩懂色av| 久久久精品日韩一区二区三区| 大鸡插骚货人人色| 国产高欧美性情一线在线| 最新的精品亚洲一区二区| 精彩欧美一区二区三区| 中文字幕在线精品的视频| 夜色成人免费观看| 精品一区二区视频在线观看| 国产情侣色综合久久有码| 大鸡巴抽插小骚逼视频免费| 亚洲AV无码一区二区三区系列| 国产日女人视频在线观看| 中国老女人 操逼 视频| 精品的极品美女一区二区三区| 啊啊啊操我视频大全| 欧美 亚洲 日本 国产| 黑人妖大鸡吧操逼| 亚洲乱熟女一区二区三区| 自拍偷拍视频颜射| 91精品国产综合久久久蜜| 免费的黄片很很操| 大肉棒操小骚穴视频| 人妻人久久精品中文字幕| 啊服慢一点插入逼逼| 黑人与日本人妻中文字幕| 美女被插入小穴涩涩视频| 欧美日韩久久久久久久久| 亚洲 自拍 欧美 一区| 粉嫩小穴被大鸡巴操视频在线观看| 丁香婷婷亚洲六月综合色| 亚洲高清中文字幕一区二区三区| 男人操女人黄片黄色| 人妻波多野结衣爽到喷水| 美女被插进去黄色| 欧美一区二区三区高清性群p| 看人妻仑乱A级毛片| 啊啊不要你那痛死爽死了直播一区| 欧美日韩国产这里只有精品| 被公侵犯中文字幕在线观看| 精品麻豆亚洲欧美|